News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
760,210 Results
Type
Article (45728)
Company Profile (333)
Press Release (714131)
Multimedia
Podcasts (126)
Webinars (22)
Section
Business (212574)
Career Advice (2122)
Deals (36577)
Drug Delivery (136)
Drug Development (82784)
Employer Resources (177)
FDA (17075)
Job Trends (15448)
News (357860)
Policy (33639)
Tag
2027 BioCapital Elite (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (1)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2749)
Accelerated approval (47)
Adcomms (26)
Allergies (176)
Alliances (52624)
ALS (213)
Alzheimer's disease (1827)
Antibody-drug conjugate (ADC) (464)
Approvals (17445)
Artificial intelligence (714)
Autoimmune disease (298)
Automation (58)
Bankruptcy (367)
Best Places to Work (11930)
BIOSECURE Act (20)
Biosimilars (222)
Biotechnology (221)
Bladder cancer (190)
Brain cancer (72)
Breast cancer (760)
Cancer (5889)
Cardiovascular disease (475)
Career advice (1805)
Career pathing (43)
CAR-T (346)
CDC (58)
Celiac Disease (3)
Cell therapy (935)
Cervical cancer (47)
Clinical research (71651)
Collaboration (2142)
Company closure (6)
Compensation (1404)
Complete response letters (80)
COVID-19 (2829)
CRISPR (115)
C-suite (1154)
Cystic fibrosis (158)
Data (7940)
Decentralized trials (3)
Denatured (45)
Depression (164)
Dermatology (87)
Diabetes (591)
Diagnostics (7216)
Digital health (57)
Diversity (13)
Diversity, equity & inclusion (45)
Drug discovery (334)
Drug pricing (203)
Drug shortages (33)
Duchenne muscular dystrophy (290)
Earnings (93820)
Editorial (67)
Employer branding (22)
Employer resources (157)
Events (124439)
Executive appointments (1115)
FDA (20857)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (16)
Frontotemporal dementia (34)
Funding (1781)
Gene editing (250)
Generative AI (63)
Gene therapy (757)
GLP-1 (1074)
Government (4839)
Grass and pollen (7)
Guidances (411)
Healthcare (19723)
HIV (83)
Huntington's disease (56)
IgA nephropathy (97)
Immunology and inflammation (292)
Immuno-oncology (94)
Indications (192)
Infectious disease (3176)
Inflammatory bowel disease (223)
Inflation Reduction Act (14)
Influenza (140)
Intellectual property (296)
Interviews (331)
IPO (17014)
IRA (51)
Job creations (3836)
Job search strategy (1502)
JPM (62)
Kidney cancer (19)
Labor market (101)
Layoffs (579)
Leadership (41)
Legal (8177)
Liver cancer (101)
Longevity (32)
Lung cancer (765)
Lymphoma (432)
Machine learning (63)
Management (63)
Manufacturing (1072)
MASH (187)
Medical device (14683)
Medtech (14809)
Mergers & acquisitions (20818)
Metabolic disorders (1511)
mRNA (229)
Multiple sclerosis (187)
NASH (17)
Neurodegenerative disease (425)
Neuropsychiatric disorders (105)
Neuroscience (3356)
Neurotech (1)
NextGen: Class of 2026 (6855)
Non-profit (4668)
Now hiring (78)
Obesity (704)
Opinion (301)
Ovarian cancer (223)
Pain (254)
Pancreatic cancer (304)
Parkinson's disease (366)
Partnered (34)
Patents (608)
Patient recruitment (683)
Peanut (65)
People (61876)
Pharmaceutical (67)
Pharmacy benefit managers (32)
Phase 1 (22497)
Phase 2 (31542)
Phase 3 (23375)
Pipeline (8804)
Policy (325)
Postmarket research (2587)
Preclinical (9675)
Press Release (71)
Prostate cancer (304)
Psychedelics (54)
Radiopharmaceuticals (344)
Rare diseases (1089)
Real estate (6300)
Recruiting (70)
Regulatory (26039)
Reports (56)
Research institute (2555)
Resumes & cover letters (365)
Rett syndrome (39)
RNA editing (24)
RSV (89)
Schizophrenia (179)
Series A (303)
Series B (218)
Service/supplier (14)
Sickle cell disease (114)
Special edition (23)
Spinal muscular atrophy (167)
Sponsored (49)
Startups (3907)
State (2)
Stomach cancer (18)
Supply chain (127)
Tariffs (87)
The Weekly (78)
Vaccines (1136)
Venture capital (114)
Weight loss (457)
Women's health (128)
Worklife (20)
Date
Last 7 days (873)
Last 30 days (3453)
Last 365 days (30758)
2026 (12708)
2025 (30957)
2024 (36211)
2023 (41132)
2022 (52397)
2021 (56991)
2020 (55610)
2019 (48406)
2018 (36438)
2017 (33539)
2016 (33138)
2015 (39357)
2014 (32941)
2013 (27985)
2012 (30243)
2011 (30847)
2010 (28809)
Location
Africa (782)
Alabama (96)
Alaska (7)
Arizona (361)
Arkansas (16)
Asia (42407)
Australia (7065)
California (13493)
Canada (3790)
China (1374)
Colorado (578)
Connecticut (592)
Delaware (415)
Europe (93438)
Florida (1997)
Georgia (440)
Hawaii (3)
Idaho (65)
Illinois (1083)
India (91)
Indiana (610)
Iowa (24)
Japan (546)
Kansas (135)
Kentucky (53)
Louisiana (42)
Maine (76)
Maryland (1609)
Massachusetts (9722)
Michigan (392)
Minnesota (737)
Mississippi (7)
Missouri (156)
Montana (36)
Nebraska (29)
Nevada (146)
New Hampshire (91)
New Jersey (3545)
New Mexico (31)
New York (3518)
North Carolina (1734)
North Dakota (11)
Northern California (6737)
Ohio (408)
Oklahoma (25)
Oregon (45)
Pennsylvania (2696)
Puerto Rico (30)
Rhode Island (51)
South America (1170)
South Carolina (86)
South Dakota (2)
Southern California (5323)
Tennessee (214)
Texas (2155)
United States (47783)
Utah (404)
Vermont (1)
Virginia (329)
Washington D.C. (81)
Washington State (1091)
West Virginia (4)
Wisconsin (139)
Wyoming (2)
760,210 Results for "liquidia technologies inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Regulatory
Liquidia Misses Full Approval for Pulmonary Hypertension Drug as Competitor Retains Market Exclusivity
The FDA on Monday only granted Liquidia’s Yutrepia tentative approval, keeping it off the U.S. market until after rival United Therapeutics’ exclusivity expires in May 2025.
August 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Medical Care Technologies Inc. (OTC Pink:MDCE) Expands AI Commercialization Strategy with Enterprise Vision Solutions
May 11, 2026
·
2 min read
Press Releases
Takara Bio USA, Inc. Validates New Class of Spatial Technology with Benchmark Study for Cancer Research
April 20, 2026
·
3 min read
Bio NC
Liquidia Corporation to Present at BofA Securities Health Care Conference 2024
Liquidia Corporation announced that Michael Kaseta, chief operating officer and chief financial officer, will provide an update on the company’s business during a fireside chat at the BofA Securities Health Care Conference 2024 on Tuesday, May 14, 2024, beginning at 5:00 p.m.
May 7, 2024
·
1 min read
Policy
FDA Misses PDUFA Date for Liquidia’s NDA for Inhaled Blood Pressure Drug
After missing its Jan. 24 PDUFA date, the regulator has extended its review period but has not issued a new decision timeframe or requested additional data, Liquidia announced Thursday.
January 25, 2024
·
1 min read
·
Kate Goodwin
Press Releases
Medical Care Technologies Inc. (OTC PINK:MDCE) Highlights Execution Momentum and Expanding AI Pipeline Following Strategic Growth Initiative
April 24, 2026
·
2 min read
Press Releases
Takara Bio USA, Inc. Launches Certified Service Provider Program to Advance Research Using NGS and Single-Cell Technologies
April 17, 2026
·
5 min read
Press Releases
Hubly Surgical awarded Breakthrough Technology Designation for Neurosurgical Products with Premier, Inc.
March 3, 2026
·
2 min read
Press Releases
Quanta System Inc.: Strengthening the U.S. Presence of Italian Laser Technology
March 1, 2026
·
4 min read
Press Releases
Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies
April 28, 2026
·
3 min read
1 of 76,021
Next
